Clinical trial
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to…
NCT00320216 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00320216 |
|---|---|
| Title | A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis |
| Official title | A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Ustekinumab, Placebo |
| Enrollment | 320 |
| Start date | Nov 1, 2003 |
| Primary completion | Jun 1, 2004 |
| Completion | Mar 1, 2005 |
| First posted | May 3, 2006 |
| Last update posted | Apr 20, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: